3-Hydroxypyrazine-2-carboxamide

3-Hydroxypyrazine-2-carboxamide (CAS 55321-99-8) is a key intermediate in the synthesis of Favipiravir (T-705/Avigan), the antiviral drug developed by Toyama Chemical that was studied in China for experimental COVID-19 treatment. It is listed at pharmaceutical grade by Hunan HuaTeng Pharmaceutical Co., Ltd., which positions itself as a global supplier of pharmaceutical intermediates offering R&D, evaluation, pilot, and commercial quantities with supporting technical documentation, though it does not manufacture this particular compound directly. It is distributed across North America, Western Europe, Eastern Europe, and Asia.